Two press releases just out extolling the virtues of Prostascint and even an honorable mention of Quadramet. Looks good long term... if there IS a long term...
First, here is a report from the current scientific meeting of the Aumerican Urology Association and Society of Nuclear Medicine. It really sound like cytogen is finally getting off its bloated, spotted behind and starting to MARKET.
Ed
----
Multiple Studies Reported at American Urology
Association and Society of Nuclear Medicine
Conferences Confirm the Clinical Utility of
ProstaScint(R)
PR Newswire - June 15, 1998 12:19
CYTO %MTC V%PRN P%PRN
Jump to first matched term
PRINCETON, N.J., June 15 /PRNewswire/ -- CYTOGEN Corporation's
(Nasdaq: CYTO) ProstaScint(R) was the subject of multiple presentations made at
the recent American Urological Association (AUA) annual meeting in San Diego and
the Society of Nuclear Medicine (SNM) annual meeting in Toronto. The various
studies confirm not only the role of ProstaScint in influencing patient management
decisions but also emphasized its cost effectiveness.
Clinicians from the University of Maryland and Loyola University presented
alternative methods for acquiring and interpreting ProstaScint images. Both involved
a special imaging technique which uses two isotopes simultaneously. This
experimental procedure, not approved by FDA, was reported to reduce the time and
costs of ProstaScint imaging. Another presentation, also from the University of
Maryland, discussed correlating ProstaScint images acquired using this dual isotope
technique with anatomic landmarks obtained via CT scan and/or MRI so as to aid
physicians in interpreting the antibody images.
Two additional studies from researchers at the Johns Hopkins' Medical Institutions
presented the role of ProstaScint in identifying lymph node spread of prostate cancer
in high-risk patients, in both the pre-surgical and recurrent disease settings. The
value of ProstaScint in identifying metastatic foci of cancer outside the prostate was
demonstrated. These studies will be reported in future publications.
A meeting of ProstaScint users which was moderated by Dr. Michael Blend of the
University of Chicago was held on Sunday, June 7 prior to the opening of the SNM
annual meeting. The meeting was attended by 200 leading clinicians from both the
United States and abroad who discussed their individual experiences with
ProstaScint. There also was a featured presentation on Quadramet(R),
CYTOGEN's therapeutic agent for metastatic bone pain.
"The data presented at these prestigious conferences confirm the earlier clinical
experience and demonstrate that ProstaScint is an invaluable diagnostic for prostate
cancer detection in appropriate patients," said John E. Bagalay, President and Chief
Executive Officer of CYTOGEN. "We are delighted with the high level of interest
in ProstaScint shown by attendees at both these meetings."
Launched in February 1997 by CYTOGEN and C.R. Bard's Urologic Division,
ProstaScint is a diagnostic-imaging agent for newly diagnosed patients at high risk
for the spread of prostate cancer and for post-prostatectomy patients with a high
suspicion that the disease has recurred or spread. ProstaScint works by binding to a
protein called Prostate Specific Membrane Antigen (PSMA) expressed by cancerous
prostate cells. Since ProstaScint is combined with a radioactive agent, a special
camera detects cells with PSMA, including metastatic cancer cells outside the
prostate. Knowing the extent and the location of the cancer is a critical factor in
selecting the best course of treatment for the patient.
Prostate cancer is the second leading cause of death from cancer in males in the
United States. The American Cancer Society estimates there will be 184,500 new
cases of prostate cancer in the United States in 1998. The disease is common in
males over sixty and accounts for over 40,000 deaths annually.
CYTOGEN is a biopharmaceutical company engaged in the development,
manufacture and commercialization of products for the targeted delivery of
diagnostics and therapeutic substances directly to disease sites. CYTOGEN has
demonstrated its ability to develop new technology from early discovery through
clinical development, regulatory approval and commercial scale biologic
manufacturing.
Information in this press release, which is not historical, is forward looking and
involves risks and uncertainties. Actual results may differ materially, for reasons
discussed in CYTOGEN's filings with the Securities and Exchange Commission,
including commercial acceptance of ProstaScint.
SOURCE CYTOGEN Corporation
/CONTACT: Corporate Communications of CYTOGEN Corporation,
609-987-8221,
or Angela Bitting of Russell-Welsh, 650-312-0700, ext. 15/ |
